Metagenomi Therapeutics, Inc. (MGX)

NASDAQ: MGX · Real-Time Price · USD

1.210

-0.020 (-1.63%)

At close: Aug 24, 2026, 4:00 PM EDT

1.214

+0.004 (0.30%)

After-hours: Aug 24, 2026, 7:41 PM EDT

Metagenomi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	39.03	41.72	27.39	140.6	184.44	39.3
Short-Term Investments	81.64	119.08	220.92	130.58	177.69	68.86
Cash & Short-Term Investments	120.66	160.8	248.31	271.18	362.13	108.15
Cash Growth	-41.14%	-35.24%	-8.43%	-25.11%	234.83%	-
Accounts Receivable	-	0.31	1.26	2.45	1.27	-
Other Receivables	0.9	1.2	1.6	1	0.3	0.49
Receivables	0.9	1.51	2.86	3.45	1.57	0.49
Prepaid Expenses	2.9	3.23	6.8	3.64	3.19	0.27
Total Current Assets	124.47	165.54	257.96	278.27	366.9	108.92
Property, Plant & Equipment	41.67	47.38	57.66	65.15	33.26	21.89
Long-Term Investments	2.15	2.15	3.45	10.68	7.81	6.42
Long-Term Deferred Charges	-	0.6	-	5.1	-	0.14
Other Long-Term Assets	5.41	5.43	5.54	5.64	6.52	4.63
Total Assets	173.7	221.1	324.6	364.84	414.49	141.99

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2.6	1.49	0.53	1.79	2.01	1.35
Accrued Expenses	7.6	6.72	8.35	11.03	7.89	3.15
Current Portion of Leases	6.24	6.03	5.59	3.43	1.52	0.69
Current Income Taxes Payable	-	-	-	3.27	1.54	-
Current Unearned Revenue	11.2	8.7	22.76	48.91	34.69	19.6
Other Current Liabilities	-	0	0.07	0.45	0.9	0.38
Total Current Liabilities	27.63	22.93	37.31	68.86	48.54	25.17
Long-Term Debt	-	-	-	-	-	30.28
Long-Term Leases	31.49	34.63	40.19	44.8	17.06	17.97
Long-Term Unearned Revenue	-	2.99	10.24	30.93	76.19	24.63
Other Long-Term Liabilities	2.02	1.95	2.01	5.08	1.03	-
Total Liabilities	61.13	62.51	89.74	149.67	142.81	98.04

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0	0	0	-	0.03	0.03
Additional Paid-In Capital	474.1	469.2	457.15	9.46	-	-
Retained Earnings	-361.41	-310.87	-223	-144.94	-76.69	-33.1
Comprehensive Income & Other	-0.12	0.26	0.71	-0.1	2.24	0.53
Total Common Equity	112.57	158.6	234.86	-135.58	-74.43	-32.54
Shareholders' Equity	112.57	158.6	234.86	215.17	271.68	43.95
Total Liabilities & Equity	173.7	221.1	324.6	364.84	414.49	141.99

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	37.72	40.66	45.78	48.23	18.57	48.93
Net Cash (Debt)	82.94	120.14	202.53	222.95	343.56	59.23
Net Cash Growth	-48.80%	-40.68%	-9.16%	-35.10%	480.08%	-
Net Cash Per Share	2.21	3.23	6.13	65.49	101.06	10.41
Filing Date Shares Outstanding	37.78	37.62	37.38	37.47	5.95	5.69
Total Common Shares Outstanding	37.78	37.62	37.42	5.95	5.95	5.69
Working Capital	96.84	142.61	220.65	209.41	318.36	83.74
Book Value Per Share	2.98	4.22	6.28	-22.80	-12.51	-5.72
Tangible Book Value	112.57	158.6	234.86	-135.58	-74.43	-32.54
Tangible Book Value Per Share	2.98	4.22	6.28	-22.80	-12.51	-5.72
Machinery	-	23.86	24.49	21.8	13.84	3.24
Construction In Progress	-	-	0.14	2.35	1.4	0.89
Leasehold Improvements	-	4.39	4.38	3.83	3.53	0.29

SEC Filings: 10-K · 10-Q